Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. | Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2025-04-15 | NCT06928363 | |
| A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome | Abnormalities, Multiple, Blood Protein Disorders, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, POEMS syndrome, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy | Not yet recruiting | Phase 1 | 2024-07-24 | NCT06518876 | |
| CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2024-06-06 | NCT06445803 |